[Correlation of Vasculogenic Mimicry with Clinicopathologic Features and Prognosis of Ovarian Carcinoma]
Overview
Authors
Affiliations
Objective: To explore the existence of vasculogenic mimicry (VM) in ovarian carcinoma and its correlationship with the clinicopathologic features and prognosis of the tumor.
Methods: A total of 84 ovarian carcinoma cases were collected with complete clinical and prognostic data. CD31 immunohistochemistry and PAS special stain were used to investigate VM in the tumor tissue. Immunohistochemical staining of VEGF, MMP-2, MMP-9, E-cadherin, beta-catenin, and Vimentin were used to explore the pathogenesis of VM.
Results: Totally 36 of 84 cases exhibited evidence of VM. FIGO classification, pathologic grades and histological types were significantly different between the VM and non-VM groups. Expression of VEGF, MMP-2, MMP-9, E-cadherin and beta-catenin were higher in the VM group than in the non-VM group. Kaplan-Meier survival curve analysis showed that cases of the VM group had a lower survival rate than that of the non-VM group (P = 0.04).
Conclusions: Vasculogenic mimicry exists in ovarian carcinoma. Ovarian carcinomas with a high grade malignancy have a high incidence of VM formation, a higher incidence of metastases and a lower survival rate. High expression of MMP-2 and MMP-9 may contribute to the formation of VM in the ovarian cancer.
Liang J, Xing H, Wu X, Zhang L, Zhao J Nan Fang Yi Ke Da Xue Xue Bao. 2019; 39(9):1065-1070.
PMID: 31640948 PMC: 6881730. DOI: 10.12122/j.issn.1673-4254.2019.09.10.
Mechanisms of Vasculogenic Mimicry in Ovarian Cancer.
Ayala-Dominguez L, Olmedo-Nieva L, Munoz-Bello J, Contreras-Paredes A, Manzo-Merino J, Martinez-Ramirez I Front Oncol. 2019; 9:998.
PMID: 31612116 PMC: 6776917. DOI: 10.3389/fonc.2019.00998.
Angara K, Borin T, Arbab A Transl Oncol. 2017; 10(4):650-660.
PMID: 28668763 PMC: 5496207. DOI: 10.1016/j.tranon.2017.04.007.
Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells.
Pinto M, Sotomayor P, Carrasco-Avino G, Corvalan A, Owen G Int J Mol Sci. 2016; 17(9).
PMID: 27608016 PMC: 5037767. DOI: 10.3390/ijms17091489.
Tang J, Wang J, Fan L, Li X, Liu N, Luo W Oncotarget. 2016; 7(17):24050-62.
PMID: 26992227 PMC: 5029683. DOI: 10.18632/oncotarget.8079.